What is Medroxyprogesterone Acetate?
Reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy.
Contraception in Females
Prevention of pregnancy.
Parenteral medroxyprogesterone: Consider benefits vs risks (e.g., loss of BMD in women of all ages, possible impact on peak bone mass in adolescents, additional impact of pregnancy and/or nursing on BMD). (See Boxed Warning and Effects on Bone under Cautions.)
Endometriosis
Management of pain associated with endometriosis. Benefit of therapy for >6 months not established. Consider benefits vs risk of BMD loss in women of all ages and the possible impact on peak bone mass in adolescents. (See Boxed Warning and Effects on Bone under Cautions.)
Amenorrhea
Treatment of secondary amenorrhea.
Uterine Bleeding
Treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.
Endometrial Carcinoma
Adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial carcinoma.
Renal Carcinoma
Has been used for treatment of metastatic renal cell carcinoma; however, other agents are preferred.
Paraphilia in Males
Management of paraphilia (e.g., homosexual, heterosexual, or bisexual pedophilia; heterosexual fetishism, voyeurism, sexual sadism, or exhibitionism; transvestism) in males.
Precocious Puberty
Management of GnRH-dependent (central) forms of precocious puberty; however, GnRH analogs generally are preferred.
Management of GnRH-independent (peripheral) forms of precocious puberty, including familial male precocious puberty (testotoxicosis) and McCune-Albright syndrome.